BioPharm International
December 01, 2019
Cover Story
32
12
The innovative spirit of biotech startups is a driving force behind the development of new therapeutic products, but building a successful biopharmaceutical company from the ground up has its risks and challenges.
December 01, 2019
Features
32
12
Accelerated approval pathways and growing demand for cell and gene therapies are putting pressure on providers of cellular starting materials, and they must ensure a steady supply.
December 01, 2019
From the Editor
32
12
Nearly four decades after the first diagnosis, the fight to treat HIV/AIDs continues.
December 01, 2019
Features
32
12
Ensuring that viral vectors are free of viral contaminants requires a focus on prevention and control.
December 01, 2019
Ask the Expert
32
12
Investigating deviations or failures of combination products needs to accommodate both the drug and device components, says Susan J. Schniepp, executive vice-president of post-approval pharma and distinguished
December 01, 2019
Features
32
12
Problems in assuring reliable drug quality and supply dampens progress in bringing lifesaving therapies to market.
December 01, 2019
Features
32
12
Downstream process development and manufacturing play a crucial role to ensure safety, quality, identity, purity, and efficacy.
December 01, 2019
Issue PDF
32
12
Click the title above to open the BioPharm International December 2019 issue in an interactive PDF format.